Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30041782 | 1.00 | LMNA (0.46) | LMNATSHRALDH1A1HSD17B10CFTR | |
| SCHEMBL29041518 | 0.89 | LMNA (0.52) | LMNATSHRALDH1A1HSD17B10CFTR | |
| SCHEMBL27867432 | 0.87 | LMNA (0.43) | LMNATSHRALDH1A1HSD17B10CFTR | |
| SCHEMBL8127577 | 0.86 | LMNA (0.46) | LMNATSHRALDH1A1HSD17B10CFTR | |
| SCHEMBL29132974 | 0.85 | KMT2A (0.46) | LMNATSHRALDH1A1HSD17B10CFTR | |
| SCHEMBL22280616 | 0.83 | KDM4E (0.49) | LMNATSHRALDH1A1HSD17B10CFTR | |
| SCHEMBL30772831 | 0.83 | TSHR (0.58) | TSHRALDH1A1HSD17B10KMT2ACA1 | |
| SCHEMBL8724253 | 0.83 | TSHR (0.58) | TSHRALDH1A1HSD17B10KMT2ACA1 | |
| SCHEMBL6637803 | 0.83 | GAA (0.44) | LMNATSHRALDH1A1HSD17B10CFTR | |
| SCHEMBL17424944 | 0.83 | LMNA (0.59) | LMNATSHRALDH1A1HSD17B10CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637473-B2 | MDM2 protein degraders | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12582722-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12582641-B2 | Sulfur-containing compound based on glutarimide skeleton and application thereof | SHANGHAITECH UNIVERSITY (CN) | 2026-03-24 | — | — | US | disclosed |
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12559506-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12528785-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250388558-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | CORETERRA THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-1528919-A2 | THERAPEUTIC USE OF ARYL AMINO ACID DERIVATIVES | Pfizer Limited (GB) | 2005-05-11 | — | — | EP | disclosed |
| US-20050026976-A1 | Isoindolinone kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
| WO-2004108672-A1 | ISOINDOLIN-1-ONE COMPOUNDS AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040138197-A1 | Therapeutic use of aryl amino acid derivatives | MAW GRAHAM NIGEL (GB) | 2004-07-15 | — | — | US | disclosed |
| WO-2004014357-A2 | THERAPEUTIC USE OF ARYL AMINO ACID DERIVATIVES | PFIZER LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
| EP-1363900-A1 | ISOINDOLE-IMIDE COMPOUNDS AS TNF-INHIBITORS | CELGENE CORPORATION (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2003-05-22 | — | — | US | disclosed |
| US-6518257-B1 | 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| WO-2002059106-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CELGENE CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| EP-1227086-A1 | 1-SUBSTITUTED PHENYL-1-(1H-IMIDAZOL-4-YL) ALCOHOLS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637473-B2 | MDM2 protein degraders | MDM2, TP53, TP53BP1 | LMNA 701/4885TSHR 1742/4885ALDH1A1 1915/4885 |
| US-12582641-B2 | Sulfur-containing compound based on glutarimide skeleton and application thereof | SUCNR1, SRD5A1, GLS | LMNA 1605/4885TSHR 1830/4885ALDH1A1 697/4885 |
| US-12528785-B2 | MDM2 degraders and uses thereof | MDM2, ADRM1, RBX1 | LMNA 3086/4885TSHR 3114/4885ALDH1A1 2101/4885 |
| US-12559506-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, CLK2 | LMNA 1596/4885TSHR 4068/4885ALDH1A1 3579/4885 |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | TNF, IKZF3, IKZF1 | LMNA 3635/4885TSHR 1322/4885ALDH1A1 2514/4885 |
| US-12582722-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | PSMB2, PSME3, PSMB3 | LMNA 2661/4885TSHR 2192/4885ALDH1A1 4614/4885 |
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | MDM2, TP53, XIAP | LMNA 1263/4885TSHR 1018/4885ALDH1A1 1320/4885 |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, PSMB2, PSMB1 | LMNA 2887/4885TSHR 3185/4885ALDH1A1 4621/4885 |
| US-20040138197-A1 | Therapeutic use of aryl amino acid derivatives | CNR1, HCRTR1, HTR6 | LMNA 632/4885TSHR 199/4885ALDH1A1 776/4885 |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, PSMB2, PSME3 | LMNA 2427/4885TSHR 3211/4885ALDH1A1 4714/4885 |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | KRAS, CRBN, HRAS | LMNA 2509/4885TSHR 2908/4885ALDH1A1 3268/4885 |
| US-20250388558-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | GRIN2C, SLC6A1, CLIC1 | LMNA 1327/4885TSHR 549/4885ALDH1A1 2260/4885 |
| US-20050026976-A1 | Isoindolinone kinase inhibitors | ABL1, LCK, MAP3K7 | LMNA 3522/4885TSHR 3759/4885ALDH1A1 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.